Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls

• DOI: 10.1016/j.nbt.2022.06.005
• Publication Date: 2022-06-29T02:22:54Z
• Authors: Amal Abu Sabaa; Qiujin Shen; Emma Bergfelt Len...; Anna Pia Enblad; Gustav Gammelgård; Daniel Molin; Anders Hein; Eva Freyhult; Masood Kamali-Mog...; Martin Höglund; Gunilla Enblad; Anna Eriksson
• Keywords: 0301 basic medicine; Proximity extension assay; Leukemia; Lymphoma; Plasma protein biomarker; Hematology; Acute leukaemia; 03 medical and health sciences; Tumor microenvironment; Tumor Microenvironment; Humans; Hematologi; Biomarkers

Aiming to accommodate the unmet need for easily accessible biomarkers with a focus on biological differences between haematological diseases, the diagnostic value of plasma proteins in acute leukaemias and lymphomas was investigated. A multiplex proximity extension assay (PEA) was used to analyze 183 proteins in diagnostic plasma samples from 251 acute leukaemia and lymphoma patients and compared with samples from 60 healthy controls. Multivariate modelling using partial least square discriminant analysis revealed highly significant differences between distinct disease subgroups and controls. The model allowed explicit distinction between leukaemia and lymphoma, with few patients misclassified. Acute leukaemia samples had higher levels of proteins associated with haemostasis, inflammation, cell differentiation and cell-matrix integration, whereas lymphoma samples demonstrated higher levels of proteins known to be associated with tumour microenvironment and lymphoma dissemination. PEA technology can be used to screen for large number of plasma protein biomarkers in low µL sample volumes, enabling the distinction between controls, acute leukaemias and lymphomas. Plasma protein profiling could help gain insights into the pathophysiology of acute leukaemia and lymphoma and the technique may be a valuable tool in the diagnosis of these diseases.